Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neumora Therapeutics, Inc. (NMRA) since 2023 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Neumora Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1885522.
Total stock buying since 2023: $118,593,772.
Total stock sales since 2023: $2,675,433.
Total stock option exercises since 2023: $130,083.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 38,076 | $64,025 | 0 | $0 |
| 2024 | 0 | $0 | 210,023 | $2,611,408 | 21,788 | $130,083 |
| 2023 | 7,293,833 | $118,593,772 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-02 | 0 | $0 | 38,076 | $64,025 | 0 | $0 |
| 2024-10 | 0 | $0 | 35,611 | $579,072 | 21,788 | $130,083 |
| 2024-09 | 0 | $0 | 74,412 | $869,484 | 0 | $0 |
| 2024-08 | 0 | $0 | 100,000 | $1,162,852 | 0 | $0 |
| 2023-11 | 542,618 | $6,160,188 | 0 | $0 | 0 | $0 |
| 2023-09 | 6,751,215 | $112,433,584 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-18 | Milligan Michael Lee (See Remarks) | Sale | 1,978 | 1.69 | 3,350 |
| 2025-02-18 | Lenz Robert A. (Head of R&D) | Sale | 5,614 | 1.67 | 9,380 |
| 2025-02-18 | Pinto Joshua (President) | Sale | 8,048 | 1.68 | 13,480 |
| 2025-02-18 | Aurora Daljit Singh (Chief Strategy Officer) | Sale | 8,565 | 1.68 | 14,346 |
| 2025-02-18 | Berns Paul L (See Remarks) | Sale | 13,871 | 1.69 | 23,469 |
| 2024-10-18 | Fust Matthew K | Sale | 14,049 | 17.04 | 239,324 |
| 2024-10-18 | Fust Matthew K | Option Ex | 14,049 | 5.66 | 79,447 |
| 2024-10-17 | Fust Matthew K | Sale | 7,739 | 17.01 | 131,640 |
| 2024-10-17 | Fust Matthew K | Option Ex | 7,739 | 6.54 | 50,636 |
| 2024-10-10 | Lenz Robert A. (Head of R&D) | Sale | 8,260 | 15.09 | 124,602 |
| 2024-10-09 | Lenz Robert A. (Head of R&D) | Sale | 5,563 | 15.01 | 83,506 |
| 2024-09-18 | Lenz Robert A. (Head of R&D) | Sale | 10,676 | 12.09 | 129,094 |
| 2024-09-17 | Lenz Robert A. (Head of R&D) | Sale | 30,788 | 11.81 | 363,729 |
| 2024-09-12 | Lenz Robert A. (Head of R&D) | Sale | 32,948 | 11.43 | 376,661 |
| 2024-08-27 | Pinto Joshua (Chief Financial Officer) | Sale | 15,693 | 11.39 | 178,806 |
| 2024-08-26 | Pinto Joshua (Chief Financial Officer) | Sale | 31,642 | 11.78 | 372,584 |
| 2024-08-23 | Pinto Joshua (Chief Financial Officer) | Sale | 24,169 | 11.59 | 279,997 |
| 2024-08-22 | Pinto Joshua (Chief Financial Officer) | Sale | 28,496 | 11.63 | 331,465 |
| 2023-11-14 | Burow Kristina (Director) | Buy | 3,357 | 11.98 | 40,216 |
| 2023-11-14 | Nelsen Robert (10% Owner) | Buy | 3,357 | 11.98 | 40,216 |
| 2023-11-13 | Burow Kristina (Director) | Buy | 31,653 | 11.75 | 371,922 |
| 2023-11-13 | Nelsen Robert (10% Owner) | Buy | 31,653 | 11.75 | 371,922 |
| 2023-11-10 | Burow Kristina (Director) | Buy | 17,275 | 11.56 | 199,699 |
| 2023-11-10 | Nelsen Robert (10% Owner) | Buy | 17,275 | 11.56 | 199,699 |
| 2023-11-09 | Burow Kristina (Director) | Buy | 31,079 | 10.53 | 327,261 |
| 2023-11-09 | Nelsen Robert (10% Owner) | Buy | 31,079 | 10.53 | 327,261 |
| 2023-11-08 | Burow Kristina (Director) | Buy | 92,251 | 11.29 | 1,041,052 |
| 2023-11-08 | Nelsen Robert (10% Owner) | Buy | 92,251 | 11.29 | 1,041,052 |
| 2023-11-07 | Burow Kristina (Director) | Buy | 30,192 | 11.50 | 347,208 |
| 2023-11-07 | Nelsen Robert (10% Owner) | Buy | 30,192 | 11.50 | 347,208 |
| 2023-11-06 | Burow Kristina (Director) | Buy | 43,082 | 11.55 | 497,597 |
| 2023-11-06 | Nelsen Robert (10% Owner) | Buy | 43,082 | 11.55 | 497,597 |
| 2023-11-03 | Burow Kristina (Director) | Buy | 22,420 | 11.38 | 255,139 |
| 2023-11-03 | Nelsen Robert (10% Owner) | Buy | 22,420 | 11.38 | 255,139 |
| 2023-09-29 | Burow Kristina (Director) | Buy | 34,560 | 13.98 | 483,148 |
| 2023-09-29 | Nelsen Robert (10% Owner) | Buy | 34,560 | 13.98 | 483,148 |
| 2023-09-28 | Burow Kristina (Director) | Buy | 41,951 | 13.38 | 561,094 |
| 2023-09-28 | Nelsen Robert (10% Owner) | Buy | 41,951 | 13.38 | 561,094 |
| 2023-09-27 | Burow Kristina (Director) | Buy | 24,504 | 12.31 | 301,644 |
| 2023-09-27 | Nelsen Robert (10% Owner) | Buy | 24,504 | 12.31 | 301,644 |
| 2023-09-26 | Burow Kristina (Director) | Buy | 34,000 | 11.73 | 398,820 |
| 2023-09-26 | Nelsen Robert (10% Owner) | Buy | 34,000 | 11.73 | 398,820 |
| 2023-09-25 | Burow Kristina (Director) | Buy | 60,740 | 11.22 | 681,806 |
| 2023-09-25 | Nelsen Robert (10% Owner) | Buy | 60,740 | 11.22 | 681,806 |
| 2023-09-22 | Burow Kristina (Director) | Buy | 40,000 | 11.14 | 445,600 |
| 2023-09-22 | Nelsen Robert (10% Owner) | Buy | 40,000 | 11.14 | 445,600 |
| 2023-09-19 | Gosebruch Henry O (President & CEO) | Buy | 15,000 | 12.62 | 189,375 |
| 2023-09-19 | Arch Venture Fund Viii Overage, L.p. (10% Owner) | Buy | 1,500,000 | 17.00 | 25,500,000 |
| 2023-09-19 | Burow Kristina | Buy | 1,500,000 | 17.00 | 25,500,000 |
| 2023-09-19 | Bybee Clinton (10% Owner) | Buy | 1,500,000 | 17.00 | 25,500,000 |
| 2023-09-19 | Amgen Inc | Buy | 1,764,705 | 17.00 | 29,999,985 |
Insider trading activities including stock purchases, stock sales, and option exercises of NMRA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Neumora Therapeutics, Inc. (symbol NMRA, CIK number 1885522) see the Securities and Exchange Commission (SEC) website.